β受体阻滞剂治疗心室颤动或无脉性室性心动过速所致心脏骤停:系统评价与Meta分析
该系统评价与Meta分析检索多个数据库,纳入3项研究共115例难治性室颤/无脉性室速心脏骤停患者,比较β受体阻滞剂与对照组。结果显示β受体阻滞剂与临时自主循环恢复(OR 14.46;95%CI 3.63-57.57)、持续自主循环恢复(OR 5.76;95%CI 1.79-18.52)、生存至入院(OR 5.76;95%CI 1.79-18.52)、生存至出院(OR 7.92;95%CI 1.85-33.89)及良好神经功能生存(OR 4.42;95%CI 1.05-18.56)相关。总体偏倚风险为中至重度,主要受参与者选择和潜在混杂影响。作者认为β受体阻滞剂可能改善从自主循环恢复到良好神经功能生存的结局,但需未来随机对照试验进一步评估。
要点
- 在难治性室颤/无脉性室速心脏骤停患者中,β受体阻滞剂与临时自主循环恢复率升高相关(OR 14.46;95%CI 3.63-57.57)。
- β受体阻滞剂与持续自主循环恢复率升高相关(OR 5.76;95%CI 1.79-18.52),与生存至入院率升高相关(OR 5.76;95%CI 1.79-18.52)。
- β受体阻滞剂与生存至出院率升高相关(OR 7.92;95%CI 1.85-33.89),与良好神经功能生存率升高相关(OR 4.42;95%CI 1.05-18.56)。
- 总体偏倚风险为中至重度,主要受参与者选择和潜在混杂影响,证据确定性有限。
适用人群与场景
- 难治性室颤或无脉性室速心脏骤停患者,即对传统高级心脏生命支持措施无反应者。
研究设计与关键结果
- 系统评价与Meta分析,纳入3项研究共115例患者,比较β受体阻滞剂与对照组。
- 临时自主循环恢复:OR 14.46(95%CI 3.63-57.57)。
- 持续自主循环恢复:OR 5.76(95%CI 1.79-18.52)。
- 生存至入院:OR 5.76(95%CI 1.79-18.52)。
- 生存至出院:OR 7.92(95%CI 1.85-33.89)。
- 良好神经功能生存:OR 4.42(95%CI 1.05-18.56)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,遵循PRISMA指南,使用Cochrane非随机干预研究偏倚风险评估工具。
- 总体偏倚风险为中至重度,主要受参与者选择和潜在混杂影响。
- 局限:未来需随机对照试验进一步评估该干预在难治性室颤/室速中的作用。
对床旁实践的改变
- 作者认为β受体阻滞剂可能改善难治性室颤/室速心脏骤停患者从自主循环恢复到良好神经功能生存的结局。
- 作者指出需未来随机对照试验进一步评估该干预。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) refers to cases that do not respond to traditional Advanced Cardiac Life Support measures and are associated with significantly lower survival rates. Beta-blockade may improve outcomes by protecting against the deleterious effects associated with epinephrine's beta-receptor effect.
OBJECTIVE: This systematic review and meta-analysis aimed to evaluate whether beta-blockade compared with control improved outcomes among patients in cardiac arrest due to refractory VF/VT.
METHODS: PubMed, Scopus, CINAHL, LILACS, the Cochrane databases, Google Scholar, and bibliographies of selected articles were assessed on September 2nd, 2019 for all studies evaluating beta-blockade versus control groups in patients with cardiac arrest due to refractory VF/VT. PRISMA guidelines were followed. Data were dual extracted into a predefined worksheet and quality analysis was performed with the Cochrane Risk of Bias in Non-randomised Studies of Interventions tool. Data were summarized and a meta-analysis was performed assessing temporary and sustained return of spontaneous circulation (ROSC), survival-to-admission, survival-to-discharge, and survival with a favorable neurologic outcome.
RESULTS: Three studies (n = 115 patients) were selected for final inclusion. Beta-blockade was associated with an increased rate of temporary ROSC (OR 14.46; 95% CI 3.63-57.57), sustained ROSC (OR 5.76; 95% CI 1.79-18.52), survival-to-admission (OR 5.76; 95% CI 1.79-18.52), survival-to-discharge (OR 7.92; 95% CI 1.85-33.89), and survival with a favorable neurologic outcome (OR 4.42; 95% CI 1.05-18.56). Overall risk of bias ranged from moderate-to-severe, which was primarily influenced by selection of participants and potential confounding. This study was registered with PROSPERO (CRD42019126902).
CONCLUSIONS: The data suggest that beta-blockade may be associated with improved outcomes ranging from ROSC to survival with a favorable neurologic outcome. Future randomized controlled trials are needed to further evaluate this intervention in refractory VF/VT.
参考来源
- Gottlieb M, Dyer S, Peksa GD, et al. Beta-blockade for the treatment of cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia: A systematic review and meta-analysis. Resuscitation. 2019. PMID: 31790759. doi:10.1016/j.resuscitation.2019.11.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。